Emcure Pharmaceuticals Ltd. (BSE: 544210, NSE: EMCURE) announced impressive financial results for Q3 FY25, showcasing strong growth across revenue and profitability metrics, led by robust international sales and effective cost management.
Key Highlights:
- Revenue from operations: ₹1,963 crore, up 17.7% YoY from ₹1,668 crore
- EBITDA: ₹362 crore, a 23.2% YoY increase from ₹294 crore
- EBITDA Margin: 18.4% versus 17.6% YoY
- Profit After Tax (PAT): ₹156 crore, up 30.3% YoY from ₹120 crore
- Domestic business sales: ₹888 crore, a 12% YoY increase
- International business sales: ₹1,075 crore, up 23% YoY
Detailed Performance:
Emcure’s domestic business contributed ₹888 crore to the topline, driven by a stable base business and in-licensed products. Meanwhile, its international operations recorded a 23% YoY growth at ₹1,075 crore, with robust performance in Rest of the World (RoW) markets, particularly with a 40% YoY surge in key regions like Canada and the EU.
The company saw its EBITDA margins expand to 18.4% due to operational efficiencies, despite a slight drop in gross profit margins to 60.1% from 62.7% in Q3 FY24, reflecting increased material costs.
Segment-wise Revenue Growth (YoY):
- Domestic: ₹888 crore (+12%)
- Rest of the World (RoW): ₹365 crore (+40%)
- EU: ₹358 crore (+1.9%)
- Canada & Others: ₹352 crore (+33.8%)
Management Commentary:
Satish Mehta, CEO and Managing Director of Emcure Pharmaceuticals, commented, “We are witnessing strong growth across international markets, underpinned by our differentiated product portfolio. Our focus on new product launches and synergies with in-licensed products continues to drive growth and enhance margins.”
With expanding demand across international markets and an increasing product base, Emcure is on track to sustain its growth momentum and improve margins further.
